The latest price target for PAVmed (NASDAQ:PAVM) was reported by Ascendiant Capital on September 10, 2024. The analyst firm set a price target for $21.00 expecting PAVM to rise to within 12 months (a possible 1491.51% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for PAVmed (NASDAQ:PAVM) was provided by Ascendiant Capital, and PAVmed maintained their buy rating.

There is no last upgrade for PAVmed

The last downgrade for PAVmed Inc happened on January 20, 2023 when Cantor Fitzgerald changed their price target from $4 to $1.5 for PAVmed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PAVmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PAVmed was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.

While ratings are subjective and will change, the latest PAVmed (PAVM) rating was a maintained with a price target of $22.00 to $21.00. The current price PAVmed (PAVM) is trading at is $1.32, which is out of the analyst’s predicted range.